MCID: PTT049
MIFTS: 53

Pituitary Adenoma, Acth-Secreting malady

Categories: Genetic diseases, Rare diseases, Reproductive diseases, Endocrine diseases, Cancer diseases

Aliases & Classifications for Pituitary Adenoma, Acth-Secreting

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 25Genetics Home Reference, 30ICD10 via Orphanet, 36MedGen, 38MeSH, 39MESH via Orphanet, 44NCIt, 47NIH Rare Diseases, 49Novoseek, 51OMIM, 53Orphanet, 61SNOMED-CT, 67UMLS, 68UMLS via Orphanet, 69UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Pituitary Adenoma, Acth-Secreting:

Name: Pituitary Adenoma, Acth-Secreting 51 12
Acth-Secreting Pituitary Adenoma 11 47 69 38 13 67
Cushing Disease 47 25 53 69
Pituitary-Dependent Cushing Syndrome 47 53
Pituitary Corticotroph Micro-Adenoma 47 53
Corticotroph Pituitary Adenoma 47 53
Pituitary-Dependant Hypercortisolism Disorder 25
Pituitary-Dependent Cushing's Disease 67
Pituitary-Dependent Cushings Disease 49
Pituitary Dependent Cushing Syndrome 47
Pituitary-Dependant Cushing Syndrome 25
Pituitary-Dependant Hypercortisolism 25
 
Pituitary Acth-Secreting Adenoma 12
Acth-Producing Pituitary Adenoma 11
Pituitary Acth Hypersecretion 25
Adrenal Gland Hyperfunction 67
Pituitary Cushing Syndrome 25
Pituitary Cushing Disease 69
Corticotroph Adenoma 11
Cushing's Disease 47
Corticotropinoma 11
Cushing Syndrome 67
Hypercortisolism 25
Aspa 69

Characteristics:

Orphanet epidemiological data:

53
cushing disease:
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: Adult

Classifications:



External Ids:

OMIM51 219090
Disease Ontology11 DOID:7004
MeSH38 D049913
NCIt44 C7462
Orphanet53 ORPHA96253
SNOMED-CT61 21109002, 254958004
ICD10 via Orphanet30 E24.0, D35.2
MESH via Orphanet39 D047748
UMLS via Orphanet68 C0221406
MedGen36 C0221406

Summaries for Pituitary Adenoma, Acth-Secreting

About this section
Genetics Home Reference:25 Cushing disease is caused by elevated levels of a hormone called cortisol, which leads to a wide variety of signs and symptoms. This condition usually occurs in adults between the ages of 20 and 50; however, children may also be affected. The first sign of this condition is usually weight gain around the trunk and in the face. Affected individuals may get stretch marks (striae) on their thighs and abdomen and bruise easily. Individuals with Cushing disease can develop a hump on their upper back caused by abnormal deposits of fat. People with this condition can have muscle weakness, severe tiredness, and progressively thin and brittle bones that are prone to fracture (osteoporosis). They also have a weakened immune system and are at an increased risk of infections. Cushing disease can cause mood disorders such as anxiety, irritability, and depression. This condition can also affect a person's concentration and memory. People with Cushing disease have an increased chance of developing high blood pressure (hypertension) and diabetes. Women with Cushing disease may experience irregular menstruation and have excessive hair growth (hirsutism) on their face, abdomen, and legs. Men with Cushing disease may have erectile dysfunction. Children with Cushing disease typically experience slow growth.

MalaCards based summary: Pituitary Adenoma, Acth-Secreting, also known as acth-secreting pituitary adenoma, is related to canavan disease and cushing's syndrome, and has symptoms including round face, thin skin and hypercortisolism. An important gene associated with Pituitary Adenoma, Acth-Secreting is USP8 (Ubiquitin Specific Peptidase 8), and among its related pathways are Glucocorticoid Pathway (HPA Axis), Pharmacodynamics and Serotonin Receptor 4/6/7 and NR3C Signaling. The drugs mitotane and aminoglutethimide have been mentioned in the context of this disorder. Affiliated tissues include pituitary, adrenal gland and bone, and related mouse phenotypes are neoplasm and no phenotypic analysis.

Disease Ontology:11 A functioning pituitary adenoma that characterized by excess cortisol a primary cause of Cushing's syndrome.

NIH Rare Diseases:47 ACTH-secreting pituitary adenoma is a condition characterized by elevated levels of a hormone called cortisol secreted by a tumor in the pituitary gland. It is part of a group of diseases that cause Cushing’s syndrome, characterized by signs and symptoms that may include weight gain around the trunk and in the face, stretch marks, easy bruising, a hump on the upper back, muscle weakness, tiredness, thin bones that are prone to fracture (osteoporosis), mood disorders and memory problems, as well as an increased risk of infections, high blood pressure and diabetes. Women may have irregular menses and a lot of hair in the body (hirsutism). It  occurs when a benign pituitary tumor (adenoma) or pituitary hyperplasia causes the adrenal glands to produce large amounts of cortisol.  Some cases are caused by somatic mutations in the AIP and the GNAS genes. Rarely, an ACTH-secreting pituitary adenoma can be inherited, either as an isolated condition or as part of a genetic syndrome (such as multiple endocrine neoplasia type 1 (MEN1) and familial isolated pituitary adenoma), but most cases are sporadic. Treatment generally involves surgery to remove the tumor and medications to decrease cortisol levels. Last updated: 12/16/2015

OMIM:51 Cushing 'disease' is a condition associated with increased blood cortisol resulting from adrenocorticotropic hormone... (219090) more...

UniProtKB/Swiss-Prot:69 ACTH-secreting pituitary adenoma: A pituitary adenoma resulting in excessive production of adrenocorticotropic hormone. This leads to hypersecretion of cortisol by the adrenal glands and ACTH-dependent Cushing syndrome. Clinical manifestations of Cushing syndrome include facial and truncal obesity, abdominal striae, muscular weakness, osteoporosis, arterial hypertension, diabetes.

Related Diseases for Pituitary Adenoma, Acth-Secreting

About this section

Diseases related to Pituitary Adenoma, Acth-Secreting via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 94)
idRelated DiseaseScoreTop Affiliating Genes
1canavan disease12.3
2cushing's syndrome11.2
3adrenal gland hyperfunction11.1
4pituitary-dependent cushing's disease11.1
5cerebral degeneration10.9
6myositis ossificans10.9
7mild canavan disease10.9
8mccune-albright syndrome, somatic, mosaic10.9
9malignant acth producing neoplasm of pituitary gland10.8
10severe canavan disease10.8
11lipodystrophy, familial partial, 210.7
12pituitary adenoma, growth hormone-secreting10.7
13acth-independent macronodular adrenal hyperplasia10.7
14familial partial lipodystrophy10.7
15adenoma10.6
16als2-related disorders10.6AIP, GNAS
17bardet-biedl syndrome10.5POMC, PRL
18lactic acidosis10.4POMC, PRL
19acute cervicitis10.4CRH, NR3C1
20colloid carcinoma of the pancreas10.4POMC, PRL
21postpartum depression10.4POMC, PRL
22hypothalamic neoplasm10.4POMC, PRL
23cone-rod dystrophy 510.4AIP, GNAS, POMC
24ehlers-danlos syndrome, type viii10.4AIP, PRL
25hyperthyroxinemia10.4CRH, PRL
26brain angioma10.4POMC, SST
27retinal microaneurysm10.4AIP, POMC, PRL
28glaucoma iridogoniodysgenesia10.3AIP, SST
29congenital epulis10.3CRH, POMC, PRL
30persistent hyperplastic primary vitreous10.3GNAS, NR3C1, POMC
31immune system organ benign neoplasm10.3POMC, PRL
32dressler's syndrome10.3CRH, POMC
33hypoglycemic coma10.3CRH, NR3C1, POMC
34blepharitis10.3CRH, POMC, PRL
35benign paroxysmal positional nystagmus10.2CRH, POMC, PRL
36pyoderma gangrenosum10.2CRH, NR3C1, POMC
37fumarate hydratase deficiency10.2GH1, GNAS, PRL
38adrenal medulla cancer10.2AIP, GNAS, SST
39multiple mitochondrial dysfunctions syndrome10.2CRH, POMC
40aneurysm or dilatation of ascending aorta10.2GH1, POMC, PRL
41fibroma10.2GNAS, SST
42hypoaldosteronism, congenital, due to cmo ii deficiency10.2NR3C1, POMC
43osseous heteroplasia, progressive10.2AIP, GNAS, POMC, PRL
44hypothryoidism, congenital, nongoitrous 410.2GH1, POMC, PRL
45pituitary deficiency due to rathke's pouch cysts10.2GH1, SST
46craniopharyngioma10.1GH1, POMC, PRL
47molybdenum cofactor deficiency b10.1GH1, POMC, PRL
4810.1CRH, POMC, SST
49lipid-rich carcinoma10.1POMC, PRL, SST
50autoimmune disease of central nervous system10.1CRH, POMC

Graphical network of the top 20 diseases related to Pituitary Adenoma, Acth-Secreting:



Diseases related to pituitary adenoma, acth-secreting

Symptoms for Pituitary Adenoma, Acth-Secreting

About this section

Symptoms by clinical synopsis from OMIM:

219090

Clinical features from OMIM:

219090

Human phenotypes related to Pituitary Adenoma, Acth-Secreting:

 63 53 (show all 74)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 round face63 53 hallmark (90%) Very frequent (99-80%) HP:0000311
2 thin skin63 53 hallmark (90%) Very frequent (99-80%) HP:0000963
3 hypercortisolism63 hallmark (90%) HP:0001578
4 truncal obesity63 53 hallmark (90%) Very frequent (99-80%) HP:0001956
5 abnormality of adipose tissue63 hallmark (90%) HP:0009124
6 neoplasm of the endocrine system63 hallmark (90%) HP:0100568
7 decreased fertility63 typical (50%) HP:0000144
8 nephrolithiasis63 53 typical (50%) Frequent (79-30%) HP:0000787
9 diabetes mellitus63 53 typical (50%) Frequent (79-30%) HP:0000819
10 hypertension63 53 typical (50%) Frequent (79-30%) HP:0000822
11 bruising susceptibility63 53 typical (50%) Frequent (79-30%) HP:0000978
12 hypertrichosis63 typical (50%) HP:0000998
13 acne63 53 typical (50%) Frequent (79-30%) HP:0001061
14 recurrent fractures63 53 typical (50%) Frequent (79-30%) HP:0002757
15 hypokalemia63 53 typical (50%) Frequent (79-30%) HP:0002900
16 reduced bone mineral density63 typical (50%) HP:0004349
17 visual impairment63 53 occasional (7.5%) Occasional (29-5%) HP:0000505
18 cataract63 53 occasional (7.5%) Occasional (29-5%) HP:0000518
19 secondary amenorrhea63 occasional (7.5%) HP:0000869
20 hypertrophic cardiomyopathy63 occasional (7.5%) HP:0001639
21 paronychia63 occasional (7.5%) HP:0001818
22 abdominal pain63 53 occasional (7.5%) Occasional (29-5%) HP:0002027
23 migraine63 occasional (7.5%) HP:0002076
24 sleep disturbance63 53 occasional (7.5%) Occasional (29-5%) HP:0002360
25 myopathy63 53 occasional (7.5%) Occasional (29-5%) HP:0003198
26 abnormality of the gastric mucosa63 occasional (7.5%) HP:0004295
27 reduced consciousness/confusion63 occasional (7.5%) HP:0004372
28 thrombophlebitis63 occasional (7.5%) HP:0004418
29 generalized hyperpigmentation63 53 occasional (7.5%) Occasional (29-5%) HP:0007440
30 aseptic necrosis63 53 occasional (7.5%) Occasional (29-5%) HP:0010885
31 telangiectasia of the skin63 occasional (7.5%) HP:0100585
32 skin ulcer63 occasional (7.5%) HP:0200042
33 glucose intolerance63 HP:0000833
34 oligomenorrhea63 HP:0000876
35 osteoporosis63 53 Frequent (79-30%) HP:0000939
36 edema63 HP:0000969
37 purpura63 HP:0000979
38 hirsutism63 HP:0001007
39 facial erythema63 HP:0001041
40 poor wound healing63 HP:0001058
41 striae distensae63 HP:0001065
42 psychotic mentation63 HP:0001345
43 mood changes63 HP:0001575
44 alkalosis63 HP:0001948
45 kyphosis63 HP:0002808
46 pituitary adenoma63 53 Very frequent (99-80%) HP:0002893
47 vertebral compression fractures63 HP:0002953
48 increased circulating acth level63 HP:0003154
49 skeletal muscle atrophy63 HP:0003202
50 biconcave vertebral bodies63 HP:0004586
51 abdominal obesity63 HP:0012743
52 abnormal fear/anxiety-related behavior63 HP:0100852
53 menorrhagia53 Frequent (79-30%)
54 visual loss53 Occasional (29-5%)
55 psychosis53 Occasional (29-5%)
56 depression53 Frequent (79-30%)
57 anxiety53 Frequent (79-30%)
58 infertility53 Frequent (79-30%)
59 lethargy53 Occasional (29-5%)
60 failure to thrive53 Very frequent (99-80%)
61 recurrent skin infections53 Occasional (29-5%)
62 cardiomyopathy53 Occasional (29-5%)
63 generalized hirsutism53 Frequent (79-30%)
64 headache53 Occasional (29-5%)
65 immunodeficiency53 Frequent (79-30%)
66 venous thrombosis53 Occasional (29-5%)
67 bipolar affective disorder53 Occasional (29-5%)
68 adrenal hyperplasia53 Very frequent (99-80%)
69 lipodystrophy53 Very frequent (99-80%)
70 onychomycosis53 Occasional (29-5%)
71 fatigue53 Frequent (79-30%)
72 teleangiectasia of the skin53 Occasional (29-5%)
73 metrorrhagia53 Frequent (79-30%)
74 precocious menopause53 Occasional (29-5%)

UMLS symptoms related to Pituitary Adenoma, Acth-Secreting:


cushingoid facies

Drugs & Therapeutics for Pituitary Adenoma, Acth-Secreting

About this section

Drugs for Pituitary Adenoma, Acth-Secreting (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 89)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
SomatostatinapprovedPhase 4, Phase 3, Phase 222938916-34-6, 51110-01-153481605
Synonyms:
growth hormone-inhibiting hormone (GHIH)
 
somatotropin release-inhibiting factor (SRIF)
somatotropin release-inhibiting hormone
2
ZincapprovedPhase 422317440-66-632051, 23994
Synonyms:
30Zn
Cinc
Zinc
Zinc ion
 
Zincum
Zink
Zn
Zn(ii)
Zn2+
3
LiraglutideapprovedPhase 4315204656-20-2
Synonyms:
204656-20-2
Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
C439759
Liraglutida
Liraglutida [INN-Spanish]
Liraglutide
Liraglutide [USAN:INN]
Liraglutide recombinant
Liraglutidum
Liraglutidum [INN-Latin]
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide
 
N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide
NN 2211
NN-2211
NN2211
NNC 90-1170
N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptide
N²⁶-(hexadecanoyl-gamma-glutamyle)-[34-arginine]GLP-1-(7-37)-peptide
UNII-839I73S42A
Victoza
nn 2211
nn2211
victoza
4
MetforminapprovedPhase 41746657-24-914219, 4091
Synonyms:
1,1-Dimethyl biguanide
1,1-Dimethylbiguanide
3-(diaminomethylidene)-1,1-dimethylguanidine
657-24-9
AC1L1HE4
AKOS000121065
Apo-Metformin
BIDD:GT0697
BPBio1_000009
BRD-K79602928-003-04-1
BSPBio_000007
BSPBio_002314
C07151
C4H11N5
CAS-1115-70-4
CCRIS 9321
CHEBI:6801
CHEMBL1431
CID4091
D04966
DB00331
DMGG
Diabetosan
Diabex
Dimethylbiguanid
Dimethylbiguanide
Dimethylbiguanidine
Dimethyldiguanide
Dimethylguanylguanidine
EINECS 211-517-8
Fluamine
Flumamine
Fortamet
Gen-Metformin
Glifage
Gliguanid
Glucophage
Glucophage XR
Glumetza
Glycon
HMS2089D19
HSCI1_000295
Haurymelin
Haurymellin
Islotin
KBio2_002310
KBio2_004878
KBio2_007446
KBio3_002790
KBioGR_002310
 
KBioSS_002312
LA-6023
LS-43899
Melbin
Metformin
Metformin (USAN/INN)
Metformin HCL
Metformin [USAN:INN:BAN]
Metformina
Metformina [DCIT]
Metformina [Spanish]
Metformine
Metformine [INN-French]
Metformine pamoate
Metforminum
Metforminum [INN-Latin]
Metiguanide
MolPort-002-929-560
MolPort-004-288-389
MolPort-005-767-418
Mylan-Metformin
N,N-Dimethylbiguanide
N,N-Dimethyldiguanide
N,N-Dimethylimidodicarbonimidic diamide
N,N-dimethylimidodicarbonimidic diamide
N1,N1-Dimethylbiguanide
NCGC00016564-01
NCGC00016564-02
NCGC00016564-03
NNDG
Novo-Metformin
Nu-Metformin
PMS-Metformin
Prestwick0_000004
Prestwick1_000004
Prestwick2_000004
Prestwick3_000004
Ran-Metformin
Ratio-Metformin
Riomet
S2483_Selleck
SPBio_001928
STK011633
Sandoz Metformin
Siofor
T5895664
Teva-Metformin
UNII-9100L32L2N
ZINC12859773
cMAP_000016
metformin
metformin hydrochloride
5Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 3, Phase 2, Early Phase 112767
6HormonesPhase 4, Phase 3, Phase 2, Early Phase 113979
7Hormone AntagonistsPhase 4, Phase 3, Phase 2, Early Phase 112778
8Dipeptidyl-Peptidase IV InhibitorsPhase 4846
9Sitagliptin PhosphatePhase 4416
10
protease inhibitorsPhase 45320
Synonyms:
 
protease inhibitors
11
LactitolPhase 4332585-86-43871
Synonyms:
4-O-b-D-Galactopyranosyl-D-glucitol, 9CI
E966
Emportal
 
Floralac
Importal
Oponaf
Portolac
12Insulin, Globin ZincPhase 44523
13Hypoglycemic AgentsPhase 4, Phase 25733
14HIV Protease InhibitorsPhase 45319
15IncretinsPhase 41537
16insulinPhase 44524
17
DopamineapprovedPhase 3, Phase 2375951-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
18
Hydrocortisoneapproved, vet_approvedPhase 3, Phase 264050-23-75754, 657311
Synonyms:
(11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione
(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
11-Hydrocortisone
11-beta-Hydrocortisone
11-beta-Hydroxycortisone
11a-Hydroxycorticosterone
11alpha-Hydroxycorticosterone
11b,17,21-Trihydroxyprogesterone
11b-Hydrocortisone
11b-Hydroxycortisone
11beta,17,21-Trihydroxyprogesterone
11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
11beta-Hydrocortisone
11beta-Hydroxycortisone
11beta-hydrocortisone
11β-hydrocortisone
17-Hydroxycorticosterone
17a-Hydroxycorticosterone
17alpha-Hydroxycorticosterone
2v95
4-Pregnen-11beta,17alpha,21-triol-3,20-dione
4-Pregnene-11alpha,21-triol 3,20-dione
4-Pregnene-11b,17a,21-triol-3,20-dione
50-23-7
8056-08-4
80562-38-5
8063-42-1
AC-12902
AC1L1L2B
ACETASOL HC
ACETIC ACID W/ HYDROCORTISONE
AI3-25006
AKOS001582651
Acticort
Acticort (TN)
Aeroseb HC
Aeroseb-HC
Ala-Cort
Ala-Scalp
Alacort
Algicirtis
Alphaderm
Amberin
Anflam
Anti-inflammatory hormone
Anucort
Anucort-HC
Anusol HC
Anusol HC (TN)
Aquacort
Aquanil HC
B48448A1-24BA-47CA-8D9E-43E5BC949386
BPBio1_000544
BRD-K93568044-001-03-1
BSPBio_000494
Balneol-hc
Barseb HC
Basan-Corti
Beta-hc
Bio-0648
C00735
C21H30O5
CCRIS 5854
CHEBI:17650
CHEMBL389621
CID5754
COR-OTICIN
CPD000653523
CaldeCORT Spray
Cetacort
Chronocort
Clear aid
Cleiton
Cobadex
Colocort
Colocort (TN)
Compound F
Compound F (kendall)
Cor-Tar-Quin
Corhydron
Cort-Dome
Cort-Quin
Cortanal
Cortef
Cortef (TN)
Cortenema
Cortesal
Corticreme
Cortifair
Cortifan
Cortifoam
Cortiment
Cortisol
Cortisol alcohol
Cortisol, Hydrocortisone
Cortisolonum
Cortisporin
Cortisporin Otico
Cortispray
Cortizol
Cortolotion
Cortonema
Cortoxide
Cortril
Cremesone
Cremicort-H
Cutisol
Cyclodextrin-encapsulated hydrocortisone
D00088
DB00741
DB07886
Delacort
Derm-Aid
Dermacort
Dermaspray
Dermil
Dermocortal
Dermolate
Dihydrocostisone
Dioderm
Dome-cort
Domolene-HC
Drotic
DuoCort
EINECS 200-020-1
EU-0100594
Ef corlin
Efcorbin
Efcortelan
Efcortelin
Eldecort
Eldercort
Epicort
Epicortisol
Epiderm H
Esiderm H
Evacort
Ficortril
Fiocortril
Flexicort
Foille Insetti
Genacort
Genacort (lotion)
Glycort
Gyno-Cortisone
H 4001
H-Cort
H0135_SIGMA
H0396_SIGMA
H0888_SIGMA
H3160_SIGMA
H4001_SIGMA
H6909_SIGMA
HC
HC #1
 
HC #4
HC (HYDROCORTISONE)
HMS1569I16
HMS2090M04
HSDB 3339
HYDROCORTISONE AND ACETIC ACID
HYDROCORTISONE IN ABSORBASE
Heb Cort
Heb-Cort
Hi-cor
Hidalone
Hidro-Colisona
Hidrocortisona
Hidrocortisona [INN-Spanish]
Hycort
Hycortol
Hycortole
Hydracort
Hydrasson
Hydro-Adreson
Hydro-Colisona
Hydro-RX
Hydro-colisona
Hydrocort
Hydrocortal
Hydrocorticosterone
Hydrocortisone
Hydrocortisone (JP15/USP/INN)
Hydrocortisone Acetate
Hydrocortisone Base
Hydrocortisone Butyrate
Hydrocortisone Sodium Phosphate
Hydrocortisone Valerate
Hydrocortisone [INN:BAN:JAN]
Hydrocortisone alcohol
Hydrocortisone base
Hydrocortisone free alcohol
Hydrocortisone solution
Hydrocortisone-Water Soluble
Hydrocortisonum
Hydrocortisonum [INN-Latin]
Hydrocortistab
Hydrocortisyl
Hydrocortone
Hydroskin
Hydroxycortisone
Hysone
Hytisone
Hytone
Hytone (TN)
Hytone lotion
Idrocortisone
Idrocortisone [DCIT]
Incortin-H
Incortin-hydrogen
Kendall'S compound F
Kendall's compound F
Komed HC
Kyypakkaus
LMST02030001
LS-7439
Lacticare HC
Lacticare-HC
Lactisona
Lopac0_000594
Lubricort
MLS000069609
MLS001148103
MLS002207135
MLS002222189
Maintasone
Medicort
Meusicort
Mildison
Milliderm
MolPort-001-794-637
NCGC00022848-06
NCGC00022848-07
NCGC00022848-09
NCGC00022848-12
NCI60_000118
NSC 10483
NSC-10483
NSC10483
Neo-Cort-Dome
Neo-Cortef
Neosporin-H Ear
Nogenic HC
Nutracort
Nystaform-HC
ORLEX HC
Optef
Otalgine
Otic-Neo-Cort-Dome
Otobiotic
Otocort
Otosone-F
Pediotic Suspension
Penecort
Permicort
Polcort H
Preparation H Hydrocortisone Cream
Prepcort
Prestwick0_000447
Prestwick1_000447
Prestwick2_000447
Prestwick3_000447
Prestwick_265
Prevex HC
Proctocort
Proctofoam
Proctozone HC
Protocort
Racet
Rectasol-HC
Rectoid
Reichstein'S substance M
Reichstein's substance M
Remederm HC
S1696_Selleck
SAM002264617
SMP1_000156
SMR000059022
SMR000653523
SPBio_002433
Sanatison
Scalp-Cort
Scalpicin Capilar
Schericur
Scheroson F
Sigmacort
Signef
Stie-cort
Stiefcorcil
Synacort
Systral Hydrocort
Tarcortin
Texacort
Texacort lotion 25
Timocort
Topicort
Transderma H
Traumaide
UNII-WI4X0X7BPJ
UPCMLD-DP133
UPCMLD-DP133:001
Uniderm
Vioform-Hydrocortisone
VoSol HC
Vytone
Zenoxone
[3H]cortisol
component of Lubricort
component of Neo-Cort-Dome
component of Otalgine
hydrocortisone
19
Mifepristoneapproved, investigationalPhase 3, Phase 214884371-65-355245
Synonyms:
(11beta,17beta)-11-(4-(Dimethylamino)-phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
(11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one
(11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
(11beta,17beta)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-prop-1-yn-1-ylestra-4,9-dien-3-one
(2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide
(8S,11R,13S,14S,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
(E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide
11-(4-DIMETHYLAMINO-PHENYL)-17-HYDROXY-13-METHYL-17-PROP-1-YNYL-1,2,6,7,8,11,12,13,14,15,16,17-DODEC AHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE
11-(4-DIMETHYLAMINO-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodec ahydro-cyclopenta[a]phenanthren-3-one
11beta-(4-(Dimethylamino)phenyl)-17-hydroxy-21-methyl-19-nor-17alpha-pregna-4,9-dien-20-m-3-on
11beta-(4-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-on
11beta-(4-(N,N-Dimethylamino)phenyl)-17alpha-(prop-1-ynyl)-delta4,9-estradiene-17beta-ol-3-one
11beta-(4-Dimethyl-?amino)-?phenyl-17beta-hydroxy-17-(1-propynyl)-?estra-4,9-dien-3-one
11beta-(p-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
122742-25-0
17-beta-Hydroxy-11-beta-(4-dimethylaminophenyl-1)-17-alpha-(prop-1-ynyl)oestra-4,9-dien-3-one
404951-53-7
83203-42-3
84371-65-3
AC1L1IOO
AC1O62SB
Ambap84371-65-3
BIDD:PXR0123
BPBio1_000262
BRD-K37270826-001-04-5
BRN 5779404
BSPBio_000238
C-1073
C07652
C29H35NO2
CHEBI:50692
CHEMBL157
CHEMBL356066
CI-1073
CID55245
CID6445533
CPD000058481
Contragest Brand of Mifepristone
Corlux
D00585
D015735
DB00834
Dacinostat
Danco Brand of Mifepristone
EC-000.2469
EU-0100801
Exelgyn Brand of Mifepristone
FT-0082666
HMS1568L20
HMS2052L05
HMS2090L22
HSCI1_000369
HSDB 6841
I14-11726
LAQ-824
LS-192513
LS-64723
Lopac0_000801
M 8046
 
M8046_SIGMA
MLS000069785
MLS001074115
Mifegyne
Mifeprex
Mifeprex (TN)
Mifepriston
Mifepristona
Mifepristona [Spanish]
Mifepristone (USAN/INN)
Mifepristone Contragest Brand
Mifepristone Danco Brand
Mifepristone Exelgyn Brand
Mifepristone [USAN:INN:BAN]
Mifepristonum
Mifepristonum [Latin]
Mifépristone
MolPort-003-849-222
NCGC00025179-05
NCGC00025179-08
NCGC00179632-01
NVP-LAQ 824
NVP-LAQ824
NVP-LAQ824, Dacinostat, LAQ824
Pictovir
Pictovir (TM)
Prestwick0_000299
Prestwick1_000299
Prestwick2_000299
Prestwick3_000299
Prestwick_570
R 38486
R-38486
R38486
RU 38486
RU 486
RU 486-6
RU-38486
RU-486
RU-486, MIFEPRISTONE
RU-486, RU-38486, Mifegyne, Mifeprex, Mifepristone
RU38486
RU486
S1095_Selleck
S1611_Selleck
SAM001246881
SMR000058481
SPBio_002457
Spectrum5_002045
TL8005515
UNII-320T6RNW1F
UNII-V10P524501
VGX-410
VGX-410C
VX-410
ZINC03831128
ZK 98296
ZK-98296
ZK98296
mifepristone
nchembio.313-comp12
20
Epinephrineapproved, vet_approvedPhase 3, Phase 293351-43-45816
Synonyms:
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-dihydroxy-a-[(methylamino)methyl]-Benzyl alcohol
(-)-3,4-dihydroxy-alpha-[(methylamino)methyl]-Benzyl alcohol
(-)-Adrenalin
(-)-Adrenaline
(-)-Epinephrine
(-)-R-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-(−)-adrenaline
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-4-[1-hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
(R)-Adrenaline
(R)-Epinephrine
(−)-adrenaline
02252_FLUKA
1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
1-Adrenalin
1-Epinephrine
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
51-43-4
51-43-4 (FREE BASE)
51028-73-0
A0173
AC-13188
AC1L1L7B
ADR ADRENALINE
ADROP
AI3-19015
Adnephrine
Adrenal
Adrenalin
Adrenalin (TN)
Adrenalin in Oil
Adrenalin-Medihaler
Adrenalina
Adrenalina [DCIT]
Adrenaline
Adrenaline (JP15)
Adrenaline/Epinephrine
Adrenalinum
Adrenamine
Adrenan
Adrenapax
Adrenasol
Adrenatrate
Adrenine
Adrenodis
Adrenohorma
Adrenosan
Adrenutol
Adrin
Adrine
Ana-Guard
Ana-Kit
Antiasthmatique
Asmatane Mist
Asthma meter mist
Asthma-nefrin
Asthmahaler Mist
Asthmanefrin
Astmahalin
Astminhal
BIDD:GT0119
Balmadren
Bernarenin
Biorenine
Bosmin
Brevirenin
Bronkaid
Bronkaid Mist
Bronkaid Suspension Mist
Bupivacaine Hcl and Epinephrine
C00788
CCRIS 4812
CHEBI:28918
CHEMBL679
CID5816
Chelafrin
Citanest Forte
Corisol
D-Epifrin
D-Epinephrine
D00095
DB00668
Drenamist
Dylephrin
Dyspne-Inhal
E4250_SIGMA
EINECS 200-098-7
EPI E Z PEN JR
EPIPEN E Z PEN
EPIPEN JR
Epi EZ Pen Jr
Epifrin
Epiglaufrin
Epinefrin
Epinefrin [Czech]
Epinefrina
Epinefrina [INN-Spanish]
Epinephran
Epinephrin
Epinephrine
Epinephrine (USP)
Epinephrine (USP/INN)
Epinephrine [USAN:INN:JAN]
Epinephrine hydrochloride
Epinephrinum
Epinephrinum [INN-Latin]
Epipen
Epipen (TN)
Epipen Auto-Injector
Epipen EZ Pen
Epipen Jr.
Epipen Jr. Auto-Injector
Epirenamine
Epirenan
Epirenin
Epitrate
Eppy
Esphygmogenina
Exadrin
 
Glaucon
Glaucosan
Glauposine
Glycirenan
HSCI1_000215
HSDB 4289
Haemostasin
Haemostatin
Hektalin
Hemisine
Hemostasin
Hemostatin
Hypernephrin
Hyporenin
IOP
Intranefrin
Iontocaine
Isoptoepinal
Kidoline
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-Adrenaline Base
L-Epinehphrine
L-Epinephrine
L-Epirenamine
L-Methylaminoethanolcatechol
L-epinephrine
LS-156
Levo-Methylaminoethanolcatechol
Levoadrenaline
Levoepinephrine
Levorenen
Levorenin
Levorenine
Levoreninum
Lopac-E-4642
Lyodrin
Lyophrin
Medihaler-Epi
Metanephrin
Methylaminoethanolcatechol
Methylarterenol
Micronefrin
Micronephrine
MolPort-002-051-368
Mucidrina
Myosthenine
Mytrate
NCGC00015417-01
NCGC00142615-01
NCGC00142615-03
NCGC00142615-04
NCGC00142615-05
NCGC00142615-06
NCGC00142615-07
NSC 62786
NSC62786
Nephridine
Nieraline
PDSP1_001120
PDSP2_001104
Paranephrin
Primatene
Primatene Mist
R-(-)-Epinephrine
R-Adrenaline
RCRA waste no. P042
Racemic Epinephrine
Racepinephrine
Rcra waste number P042
Renagladin
Renaglandin
Renaglandulin
Renaleptine
Renalina
Renoform
Renostypricin
Renostypticin
Renostyptin
SMP1_000227
ST069368
SUS-PHRINE SULFITE-FREE
Scurenaline
Septocaine
Simplene
Sindrenina
Soladren
Sphygmogenin
Stryptirenal
Styptirenal
Supracapsulin
Supradin
Supranefran
Supranephrane
Supranephrine
Supranol
Suprarenaline
Suprarenin
Suprel
Surenine
Surrenine
Sus-Phrine
Sus-phrine
Susphrine
Sympathin I
Takamina
Takamine
Tokamina
Tonogen
Twinject
Twinject 0.15
Twinject 0.3
Twinject 0.30
UNII-YKH834O4BH
Vaponefrin
Vasoconstrictine
Vasoconstrictor
Vasodrine
Vasoton
Vasotonin
adrenaline
bmse000316
d-Adrenaline
epinephrine
l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
l-Adrenalin
l-Adrenaline
l-Epinephine
l-Epinephrine (synthetic)
l-Epirenamine
l-Methylaminoethanolcatechol
levoepinephrine
nchembio747-comp9
21
CabergolineapprovedPhase 3, Phase 24681409-90-754746
Synonyms:
(8R)-6-Allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)Propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide
1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
1-Ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
1-[(6-Allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate
1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
81409-90-7
85329-89-1 (diphosphate)
AC-14150
AC1L1HO0
AC1Q5OQ0
BIDD:GT0775
BRD-K86882815-001-01-6
BRN 6020775
C08187
C26H37N5O2
CG-101
CHEBI:3286
 
CHEMBL1201087
CID54746
Cabaser
Cabaser (TN)
Cabaseril
Cabergolina
Cabergolina [Spanish]
Cabergoline
Cabergoline (JAN/USAN/INN)
Cabergoline [USAN:BAN:INN]
Cabergolinum
Cabergolinum [Latin]
D00987
DB00248
Dostinex
Dostinex (TN)
FCE-21336
FT-0081285
Galastop
HMS2090A09
LS-64370
MolPort-003-845-557
Sogilen
UNII-LL60K9J05T
cabergoline
22
Octreotideapproved, investigationalPhase 321383150-76-9383414, 6400441
Synonyms:
(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-Aminobutyl)-19-((2-amino-3-phenylpropanoyl)amino)-16-benzyl-7-(1-hydroxyethyl)-N-(2-hydroxy-1-(hydroxymethyl)propyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaa
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide
79517-01-4 (acetate salt)
83150-76-9
AC1L1GVU
AC1L8LCD
AC1L9M4X
C07306
C5H12O2.C4H10
CHEBI:427278
CHEBI:611465
CHEMBL1680
CID383414
CID448601
CID54374
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide
D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2->7)-disulfide
D00442
DRG-0115
HMS2090C09
HS-2020
 
L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L- threonyl-N-(2-hydroxy-1-(hydroxymethyl)propyl)-, cyclic (2->7)-disulfide, (R-(R*
L000453
LS-177735
LS-187135
Longastatin
NCGC00181796-01
NCI60_025753
Octreotida
Octreotida [Spanish]
Octreotide
Octreotide (USAN/INN)
Octreotide Acetate Salt
Octreotide [USAN:INN:BAN]
Octreotide-LAR
Octreotidum
Octreotidum [Latin]
Octrotide
SAN 201-995
SM 201-995
SMS 201-995
SMS-201-995
Sandostatine
Sandoz 201-995
UNII-RWM8CCW8GP
nchembio.184-comp3
zacycloicosane-4-carboxamide acetate
23
Lidocaineapproved, vet_approvedPhase 2, Phase 31226137-58-63676
Synonyms:
.alpha.-(Diethylamino)-2,6-acetoxylidide
.alpha.-Diethylamino-2,6-dimethylacetanilide
.alpha.-Diethylaminoaceto-2,6-xylidide
.omega.-Diethylamino-2,6-dimethylacetanilide
137-58-6
2-(Diethylamino)-2',6'-acetoxylidide
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide
2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide
2-Diethylamino-N-(2,6-dimethylphenyl)acetamide
4-12-00-02538 (Beilstein Handbook Reference)
6108-05-0 (MONOHYDROCHLORIDE MONOHYDRATE))
6108-05-0 (mono-hydrochloride, mono-hydrate)
73-78-9 (mono-hydrochloride)
AB00053581
AC-10282
AC1L1GGQ
AC1Q2Z7J
AKOS001026768
ARONIS23855
After Burn Double Strength Gel
After Burn Double Strength Spray
After Burn Gel
After Burn Spray
Alphacaine
Anestacon
Anestacon Jelly
BIDD:GT0342
BPBio1_000197
BRD-K52662033-001-02-6
BRD-K52662033-003-05-5
BRN 2215784
BSPBio_000179
BSPBio_001359
BSPBio_003004
Bio-0767
Bio1_000379
Bio1_000868
Bio1_001357
Bio2_000079
Bio2_000559
C07073
C14H22N2O
CAS-73-78-9
CDS1_000283
CHEBI:6456
CHEMBL79
CID3676
CPD000058189
Cappicaine
Cito optadren
Cuivasil
D00358
DB00281
Dalcaine
Dentipatch
Dentipatch (TN)
DermaFlex
Diethylaminoaceto-2,6-xylidide
Dilocaine
DivK1c_000174
DivK1c_001323
Duncaine
EINECS 205-302-8
ELA-Max
EMBOLEX
Emla
Emla Cream
Esracaine
FT-0082378
Gravocain
HMS1791D21
HMS1989D21
HMS2051C21
HMS2089E15
HMS548M19
HSDB 3350
I01-2704
IDI1_000174
IDI1_033829
Isicaina
Isicaine
Jetocaine
KBio1_000174
KBio2_000079
KBio2_001598
KBio2_002647
KBio2_004166
KBio2_005215
KBio2_006734
KBio3_000157
KBio3_000158
KBio3_002224
KBioGR_000079
KBioGR_000599
KBioSS_000079
KBioSS_001598
L-Caine
L0156
L1026_SIGMA
L7757_SIGMA
LIDOCAINE (73-58-6 (MONOHYDROCHLORIDE)
LIDOPEN
LQZ
 
LS-805
Lanabiotic
Leostesin
Lida-Mantle
Lidocaina
Lidocaina [INN-Spanish]
Lidocaine (JP15/USP/INN)
Lidocaine (VAN)
Lidocaine Carbonate
Lidocaine Hydrocarbonate
Lidocaine Monohydrochloride
Lidocaine [USAN:INN:JAN]
Lidocainum
Lidocainum [INN-Latin]
Lidocaton
Lidoderm
Lidoject-1
Lidoject-2
Lignocaine
Lignocainum
Lingocaine
Lopac-L-5647
Lopac0_000669
MLS000069724
MLS000758263
MLS001074177
Maricaine
Maybridge1_002571
MolPort-001-783-478
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide
N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
NCGC00015611-01
NCGC00015611-02
NCGC00015611-03
NCGC00015611-04
NCGC00015611-14
NCGC00022176-05
NCGC00022176-06
NCGC00022176-07
NCGC00022176-08
NCGC00022176-09
NINDS_000174
NSC 40030
NSC40030
Norwood Sunburn Spray
Octocaine
Octocaine-100
Octocaine-50
Prestwick0_000050
Prestwick1_000050
Prestwick2_000050
Prestwick3_000050
Remicaine
Rocephin Kit
Rucaina
S1357_Selleck
SAM001247018
SMR000058189
SPBio_001525
SPBio_002100
STK552033
Solarcaine
Solarcaine aloe extra burn relief cream
Solcain
Spectrum2_001343
Spectrum3_001392
Spectrum4_000070
Spectrum5_001549
Spectrum_001118
UNII-98PI200987
WLN: 2N2 & 1VMR B1 F1
Xilina
Xilocaina
Xilocaina [Italian]
Xllina
Xycaine
Xylestesin
Xylesthesin
Xylocain
Xylocaine
Xylocaine (TN)
Xylocaine 5% Spinal
Xylocaine CO2
Xylocaine Dental Ointment
Xylocaine Endotracheal
Xylocaine Test Dose
Xylocaine Viscous
Xylocaine-MPF
Xylocaine-MPF with Glucose
Xylocaine-Mpf
Xylocaine-Mpf with Glucose
Xylocard
Xylocitin
Xyloneural (free base)
Xylotox
Zilactin-L
Zingo
alfa-Dietilamino-2,6-dimetilacetanilide
alfa-Dietilamino-2,6-dimetilacetanilide [Italian]
alpha-Diethylamino-2,6-dimethylacetanilide
alpha-diethylamino-2,6-dimethylacetanilide
lidocaine
nchembio.65-comp16
α-diethylamino-2,6-dimethylacetanilide
24AnestheticsPhase 2, Phase 39001
25beta-endorphinPhase 3, Phase 2133
26Epinephryl boratePhase 3, Phase 2933
27Interleukin 1 Receptor Antagonist ProteinPhase 396
28Adrenocorticotropic HormonePhase 3, Phase 2, Early Phase 1155
29Antirheumatic AgentsPhase 310627
30RacepinephrinePhase 3, Phase 2933
31Melanocyte-Stimulating HormonesPhase 3, Phase 2132
32Dopamine agonistsPhase 3, Phase 2618
33Luteolytic AgentsPhase 3, Phase 2294
34Hydrocortisone acetatePhase 3, Phase 2640
35Hydrocortisone 17-butyrate 21-propionatePhase 3, Phase 2640
36Cortisol succinatePhase 3, Phase 2640
37Dopamine AgentsPhase 3, Phase 23759
38Antiparkinson AgentsPhase 3, Phase 21527
39Contraceptives, OralPhase 3, Phase 21292
40Neurotransmitter AgentsPhase 3, Phase 217734
41Contraceptives, PostcoitalPhase 3, Phase 2169
42Contraceptive AgentsPhase 3, Phase 21901
43Autonomic AgentsPhase 2, Phase 39774
44Anti-Asthmatic AgentsPhase 2, Phase 33369
45glucocorticoidsPhase 2, Phase 34920
46Bronchodilator AgentsPhase 2, Phase 32856
47Respiratory System AgentsPhase 2, Phase 34818
48Vasoconstrictor AgentsPhase 2, Phase 32027
49Peripheral Nervous System AgentsPhase 2, Phase 322776
50MydriaticsPhase 2, Phase 3763

Interventional clinical trials:

(show top 50)    (show all 53)
idNameStatusNCT IDPhase
1Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or AcromegalyRecruitingNCT02060383Phase 4
2Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.RecruitingNCT01794793Phase 4
3Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's DiseaseCompletedNCT00434148Phase 3
4Study of Cabergoline in Treatment of Corticotroph Pituitary TumorCompletedNCT00889525Phase 3
5Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's SyndromeCompletedNCT01371565Phase 3
6An Extension Study of CORLUX in the Treatment of Endogenous Cushing's SyndromeCompletedNCT00936741Phase 3
7A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's SyndromeCompletedNCT00569582Phase 3
8Effects of IL-1 Beta on the HPA-axis in Obese PersonsCompletedNCT02227420Phase 3
9Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's DiseaseRecruitingNCT02180217Phase 3
10Efficacy and Safety Evaluation of Osilodrostat in Cushing's DiseaseRecruitingNCT02697734Phase 3
11Ga-68-DOTATOC -PET in the Management of Pituitary TumoursRecruitingNCT02419664Phase 3
12Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's DiseaseActive, not recruitingNCT01374906Phase 3
13An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.Active, not recruitingNCT01582061Phase 3
14Dynamic Hormone Diagnostics in Endocrine DiseaseNot yet recruitingNCT02934399Phase 2, Phase 3
15Mifepristone in Children With Refractory Cushing's DiseaseWithdrawnNCT01925092Phase 3
16Preoperative Bexarotene Treatment for Cushing's DiseaseUnknown statusNCT00845351Phase 1, Phase 2
17Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's DiseaseCompletedNCT00171951Phase 2
18A Study to Assess SOM230 in Patients With Pituitary Cushing's DiseaseCompletedNCT00088608Phase 2
19Treatment of Cushing's Disease With R-roscovitineRecruitingNCT02160730Phase 2
20Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's DiseaseRecruitingNCT02484755Phase 2
21Study of Efficacy and Safety of Osilodrostat in Cushing's SyndromeRecruitingNCT02468193Phase 2
22Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard TherapyRecruitingNCT00939523Phase 2
23Study to Evaluate CORT125134 in Patients With Cushing's SyndromeRecruitingNCT02804750Phase 2
24Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's DiseaseActive, not recruitingNCT01915303Phase 2
25Safety and Efficacy of LCI699 in Cushing's Disease Patients.Active, not recruitingNCT01331239Phase 2
26Pasireotide LAR Therapy of Silent Corticotroph Pituitary TumorsNot yet recruitingNCT02749227Phase 2
27Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical TreatmentNot yet recruitingNCT02713776Phase 2
28Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)TerminatedNCT00612066Phase 2
29Rosiglitazone in Treating Patients With Pituitary TumorsTerminatedNCT00616642Phase 2
30Pasireotide Therapy in Patients With Nelson's SyndromeTerminatedNCT01617733Phase 2
31Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) SecretionTerminatedNCT00422201Phase 2
32Phase II Study of SOM230 in Patients With Recurrent or Progressive MeningiomaTerminatedNCT00813592Phase 2
33Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine OriginTerminatedNCT00958841Phase 2
34Study of Depression, Peptides, and Steroids in Cushing's SyndromeUnknown statusNCT00004334
35Anesthesia Management of Retroperitoneal AdrenalectomiesUnknown statusNCT00894335
36The Factors Associated With the Recurrence in Patients With Cushing DiseaseCompletedNCT02233335
37Cognition, Steroids, and Imaging in Cushings DiseaseCompletedNCT00081341
38Jugular Vein Sampling for Hormone Levels for the Diagnosis of Cushing SyndromeCompletedNCT00001453
39Examination of Brain Serotonin Receptors in Patients With Mood DisordersCompletedNCT00026832
40Obesity as a Risk Factor for Musculoskeletal Diseases in the U.S. Air Force: Associations and Implications for Force ReadinessCompletedNCT01613001
41Cushing's Disease ComplicationsRecruitingNCT02568982
42Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's DiseaseRecruitingNCT02310269
43Effects of Hormone Stimulation on Brain Scans for Cushing s DiseaseRecruitingNCT01459237Early Phase 1
44Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education ToolsRecruitingNCT01775332
45Mutations of Glucocorticoid Receptor in Bilateral Adrenal HyperplasiaRecruitingNCT02810496
46An Investigation of Pituitary Tumors and Related Hypothalmic DisordersRecruitingNCT00001595
47Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B.RecruitingNCT02651844
48Adrenal Venous Sampling in Patients With Overt or Subclinical Cushings Syndrome, and Bilateral Adrenal TumorsRecruitingNCT02543697
49Cushing´s Disease Epidemiology in SwedenActive, not recruitingNCT02350153
50Rhinological Outcomes in Endonasal Pituitary SurgeryActive, not recruitingNCT01504399

Search NIH Clinical Center for Pituitary Adenoma, Acth-Secreting

Inferred drug relations via UMLS67/NDF-RT45:


Cochrane evidence based reviews: acth-secreting pituitary adenoma

Genetic Tests for Pituitary Adenoma, Acth-Secreting

About this section

Anatomical Context for Pituitary Adenoma, Acth-Secreting

About this section

MalaCards organs/tissues related to Pituitary Adenoma, Acth-Secreting:

35
Pituitary, Adrenal gland, Bone, Skin, Brain, Skeletal muscle

Animal Models for Pituitary Adenoma, Acth-Secreting or affiliated genes

About this section

MGI Mouse Phenotypes related to Pituitary Adenoma, Acth-Secreting:

40 (show all 16)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020068.6AIP, DRD2, GNAI2, GNAS, POMC, PRL
2MP:00030128.3CRH, DRD2, GNAS, NR3C1, POMC, SST
3MP:00053757.8CRH, DRD2, GNAS, NR3C1, PCSK1, POMC
4MP:00053907.8CRH, DRD2, GNAI2, GNAS, NR3C1, PRKCD
5MP:00107717.8AIP, CRH, DRD2, GNAS, NR3C1, POMC
6MP:00053677.6CRH, DRD2, GNAS, NR3C1, POMC, PRKCD
7MP:00053847.5AIP, CRH, DRD2, GNAI2, GNAS, NR3C1
8MP:00053707.2AIP, CRH, DRD2, GNAI2, GNAS, NR3C1
9MP:00053866.9CRH, DRD2, GNAI2, GNAS, NR3C1, PCSK1
10MP:00053856.8AIP, DRD2, GNAI2, GNAS, NR3C1, PCSK1
11MP:00036316.5CRH, DRD2, GNAI2, GNAS, NR3C1, POMC
12MP:00053796.5AIP, CRH, DRD2, GNAI2, GNAS, NR3C1
13MP:00053876.4CRH, DRD2, GNAI2, GNAS, NR3C1, PCSK1
14MP:00107686.2AIP, DRD2, GNAI2, GNAS, NR3C1, PAM16
15MP:00053785.8AIP, CRH, DRD2, GNAI2, GNAS, NR3C1
16MP:00053765.3AIP, CRH, DRD2, GNAI2, GNAS, NR3C1

Publications for Pituitary Adenoma, Acth-Secreting

About this section

Variations for Pituitary Adenoma, Acth-Secreting

About this section

Clinvar genetic disease variations for Pituitary Adenoma, Acth-Secreting:

5 (show all 11)
id Gene Variation Type Significance SNP ID Assembly Location
1GNAI2NM_002070.3(GNAI2): c.535C> G (p.Arg179Gly)SNVPathogenicrs137853226GRCh37Chr 3, 50293694: 50293694
2GNASNM_000516.5(GNAS): c.601C> T (p.Arg201Cys)SNVPathogenicrs11554273GRCh37Chr 20, 57484420: 57484420
3GNASNM_000516.5(GNAS): c.602G> A (p.Arg201His)SNVPathogenicrs121913495GRCh37Chr 20, 57484421: 57484421
4GNASNM_000516.5(GNAS): c.680A> G (p.Gln227Arg)SNVPathogenicrs121913494GRCh37Chr 20, 57484596: 57484596
5GNASNM_001077488.3(GNAS): c.684G> C (p.Gln228His)SNVPathogenicrs137854533GRCh37Chr 20, 57484597: 57484597
6GNASNM_000516.5(GNAS): c.601C> A (p.Arg201Ser)SNVPathogenicrs11554273GRCh37Chr 20, 57484420: 57484420
7USP8NM_005154.4(USP8): c.2155_2157delTCC (p.Ser719del)deletionPathogenicrs672601306GRCh38Chr 15, 50490446: 50490448
8USP8NM_005154.4(USP8): c.2152T> C (p.Ser718Pro)SNVPathogenicrs672601307GRCh38Chr 15, 50490443: 50490443
9USP8NM_005154.4(USP8): c.2153C> G (p.Ser718Cys)SNVPathogenicrs672601308GRCh38Chr 15, 50490444: 50490444
10USP8NM_005154.4(USP8): c.2159C> G (p.Pro720Arg)SNVPathogenicrs672601311GRCh38Chr 15, 50490450: 50490450
11AIPNM_003977.3(AIP): c.911G> A (p.Arg304Gln)SNVPathogenicrs104894190GRCh37Chr 11, 67258382: 67258382

Cosmic variations for Pituitary Adenoma, Acth-Secreting:

8 (show all 25)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM303944PIK3CApituitary,NS,adenoma,ACTHc.2984C>Ap.A995D55
2COSM27896GNASpituitary,NS,adenoma,ACTHc.680A>Gp.Q227R55
3COSM1749198USP8pituitary,NS,adenoma,ACTHc.2159C>Gp.P720R55
4COSM28544PIK3CApituitary,NS,adenoma,ACTHc.3026G>Ap.G1009E55
5COSM22589MEN1pituitary,NS,adenoma,ACTHc.1230C>Ap.F410L55
6COSM4997287USP8pituitary,NS,adenoma,ACTHc.2152T>Cp.S718P55
7COSM482HRASpituitary,NS,adenoma,ACTHc.34G>Cp.G12R55
8COSM27887GNASpituitary,NS,adenoma,ACTHc.601C>Tp.R201C55
9COSM5667CTNNB1adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producingc.134C>Tp.S45F6
10COSM27895GNASadrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producingc.602G>Ap.R201H6
11COSM4167506PRKACAadrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producingc.617T>Gp.L206R6
12COSM476BRAFadrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producingc.1799T>Ap.V600E6
13COSM5663CTNNB1adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producingc.133T>Cp.S45P6
14COSM5693CTNNB1adrenal gland,adrenal gland,adrenal cortical carcinoma,cortisol producingc.118A>Gp.T40A6
15COSM326321RB1adrenal gland,adrenal gland,adrenal cortical carcinoma,cortisol producingc.1994T>Gp.L665R6
16COSM4962873GNASadrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producingc.679C>Gp.Q227E6
17COSM5679CTNNB1adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producingc.110C>Gp.S37C6
18COSM27899GNASadrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producingc.601C>Ap.R201S6
19COSM45444TP53adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producingc.587G>Tp.R196L6
20COSM5681CTNNB1adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producingc.95A>Gp.D32G6
21COSM225014RB1adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producingc.1960G>Ap.V654M6
22COSM43555TP53adrenal gland,adrenal gland,adrenal cortical adenoma,cortisol producingc.736A>Gp.M246V6
23COSM43939TP53skin,face,other,hyperplasiac.632C>Tp.T211I3
24COSM10654TP53skin,face,other,hyperplasiac.637C>Tp.R213*3
25COSM10995TP53skin,face,other,hyperplasiac.580C>Tp.L194F3

Expression for genes affiliated with Pituitary Adenoma, Acth-Secreting

About this section
Search GEO for disease gene expression data for Pituitary Adenoma, Acth-Secreting.

Pathways for genes affiliated with Pituitary Adenoma, Acth-Secreting

About this section

Pathways related to Pituitary Adenoma, Acth-Secreting according to GeneCards Suite gene sharing:

(show all 17)
idSuper pathwaysScoreTop Affiliating Genes
19.9CRH, POMC
29.9GNAS, NR3C1
3
Show member pathways
9.7GH1, PRL
49.7CRH, GNAI2, GNAS
59.5NR3C1, POMC, PRL
6
Show member pathways
9.4GNAI2, GNAS, SST
79.4GNAI2, GNAS, PRKCD
89.4CRH, GNAI2, GNAS, POMC
9
Show member pathways
9.1DRD2, GNAI2, GNAS
10
Show member pathways
9.1CRH, GNAI2, GNAS, PRKCD
11
Show member pathways
8.8GH1, NR3C1, PRKCD, PRL
128.6DRD2, GNAI2, GNAS, PRKCD
138.4CRH, GNAI2, GNAS, POMC, PRKCD, TBX19
14
Show member pathways
8.4CRH, GH1, GNAI2, GNAS, POMC, PRKCD
15
Show member pathways
8.3GH1, GNAI2, GNAS, NR3C1, PRKCD, PRL
16
Show member pathways
6.9CRH, DRD2, GH1, GNAI2, GNAS, NR3C1
17
Show member pathways
6.2CRH, DRD2, GH1, GNAI2, GNAS, NR3C1

GO Terms for genes affiliated with Pituitary Adenoma, Acth-Secreting

About this section

Cellular components related to Pituitary Adenoma, Acth-Secreting according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1secretory granule lumenGO:00347749.6PCSK1, POMC

Biological processes related to Pituitary Adenoma, Acth-Secreting according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1hormone-mediated apoptotic signaling pathwayGO:000862810.2CRH, SST
2JAK-STAT cascade involved in growth hormone signaling pathwayGO:006039710.2GH1, PRL
3positive regulation of JAK-STAT cascadeGO:004642710.1GH1, PRL
4peptide hormone processingGO:001648610.1PCSK1, POMC
5synaptic transmission, dopaminergicGO:00019639.4CRH, DRD2
6positive regulation of receptor internalizationGO:00020929.3DRD2, GH1
7negative regulation of adenylate cyclase activityGO:00071949.1DRD2, GNAI2
8signal transductionGO:00071658.5AIP, CRH, GNAI2, NR3C1, POMC, PRKCD
9response to drugGO:00424938.5CRH, DRD2, GNAS, SST

Molecular functions related to Pituitary Adenoma, Acth-Secreting according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1G-protein beta/gamma-subunit complex bindingGO:003168310.3GNAI2, GNAS
2prolactin receptor bindingGO:000514810.2GH1, PRL
3corticotropin-releasing hormone receptor 1 bindingGO:005143010.1CRH, GNAS
4ionotropic glutamate receptor bindingGO:00352559.4DRD2, GNAS
5hormone activityGO:00051798.7CRH, GH1, POMC, PRL, SST

Sources for Pituitary Adenoma, Acth-Secreting

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet